Wockhardt is a global pharmaceutical and biotechnology organization engaged in manufacturing finished dosage formulations, injectables, biopharmaceuticals, orals and topicals (creams and ointments)vaccines in India, the United States, Europe, and internationally. The company offers generic products comprising injectables, such as cephalosporins and non-cephalosporins, molecules and value-added generics. Its biopharmaceutical products include Glaritus, an insulin analog, Wosulin, an r-DNA insulin, Wepox, a recombinant erythropoietin that is used in the treatment of anemia caused by cancer and chronic renal failure, and Biovac-B, a hepatitis B vaccine.Wockhardt has an operating revenue of Rs. 2,651.00 Cr with a healthy balance sheet . In the technical point view , its trading close to 200DMA and above 50EMA and 100EMA. Stock has already gained more than 20% in this month. if it keep this trend , then the upward movement never ends. Probably 1000 levels are not so harder in this trend .
交易進行:
Going smoothly
交易進行:
Looking to cross 300 level now